Moleculin Biotech, Inc. MBRX
Moleculin Biotech, Inc. (Nasdaq: MBRX) is an oncology drug developer. Its lead program, Annamycin (MIRACLE trial), is in Phase 2 for Relapsed/refractory acute myeloid leukemia (with cytarabine). Its next catalyst on record is Annamycin: Second interim analysis of MB-108 trial expected in early 2027. (H1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: Annamycin — Second interim analysis of MB-108 trial expected in early 2027. (H1 2027). 1 catalyst on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| Annamycin (MIRACLE) | R/R AML, pivotal Phase 2/3 | small molecule | Phase 2 |
| Annamycin | Soft tissue sarcoma lung metastases / pancreatic cancer Phase 1B/2 | small molecule | Phase 1 |
| WP1066 | Glioblastoma / brain tumors Phase 1B/2 | small molecule | Phase 1 |
| MB-109 / MB-110 | Combination programs | small molecule | Pre-clinical |
Recent results and decisions
- Nov 4, 2026positive First interim analysis of pivotal Phase 2/3 trial shows complete remission rates of 43% and 36% in Annamycin treatment arms versus 12% in placebo arm for relapsed/refractory AML patients, with no cardiotoxicity observed.
Among the first 45 randomized patients evaluated, complete remission rates were 43% and 36% in the two Annamycin treatment arms, respectively, compared to 12% in the placebo arm.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 2 oncology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.